Selexipag Therapy Effective For Pulmonary Hypertension Patients Pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD) presents a significant clinical challenge, with affected patients often experiencing worse outcomes than those with idiopathic pulmonary arterial hypertension (IPAH). Although earlier short-term studies suggested a limited response to PAH-specific therapies in PAH-CTD patients, recent
Tag: pulmonology
Microbial Sinus Dynamics In Cystic Fibrosis Lung Transplant Patients
Microbial Sinus Dynamics In Cystic Fibrosis Lung Transplant Patients The upper airways in individuals with cystic fibrosis (PwCF) are constantly exposed to inhaled microbes. The sinonasal cavity is identified as the initial site colonized by pathogenic microbes with the potential to impact the lower respiratory tract. Chronic rhinosinusitis (C.R.S.), a prevalent
Lung Cancer Surgery: Thoracoscopic Lobectomy And Wound Infection Rates
Lung Cancer Surgery: Thoracoscopic Lobectomy And Wound Infection Rates Overview This meta-analysis rigorously examines the impact of thoracoscopic lobectomy on wound infection rates and complications among lung cancer patients. Through a comprehensive search across multiple databases, including PubMed, Embase, and Cochrane Library, among others, this study identified 21 relevant studies encompassing 2,118
Salbutamol: A Safety Meta-Analysis
Salbutamol: A Safety Meta-Analysis Overview Salbutamol, a widely used bronchospasm reliever, has been insufficiently scrutinized for potential risks. In a meta-analysis of 58 randomized controlled trials with 12,961 participants, the study unearthed a 34% incidence of total adverse events (AEs). Notably, severe AEs stood at 2%, and treatment discontinuation was 3%. Subgroup
Mepolizumab Effectiveness In Asthma, Rhinosinusitis, and Sinus Surgery Patients
Mepolizumab Effectiveness In Asthma, Rhinosinusitis, and Sinus Surgery Patients Overview In this retrospective cohort study utilizing IQVIA PharMetrics Plus claims data, the effectiveness of mepolizumab, a humanized anti-interleukin 5 monoclonal antibody, was explored in a real-world setting for U.S. patients with severe asthma and comorbid chronic rhinosinusitis (CRS) with or without sinus
